Dr Jane Sosabowski

BSc (Hons), MSc, PhD
Reader in Preclinical Molecular Imaging
Group Leader
Research Focus

My main interests are in radiopharmaceutical development and the use of pre-clinical molecular imaging in drug development, especially biopharmaceuticals.

Key Publications

Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med (2009) 50, 2082-9. PMID: 19910426

Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nature Protocols (2006) 1, 972-976. PMID: 17406332

Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivoCancer Biother Radiopharm (2010) 25, 89-95. PMID: 20187801

Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci (2007) 31, 102-11. PMID: 17387005

Major Funding
  • 2018-2021- Barts Charity, Development of a Gallium-68 PET Clinical Imaging Service, £499,993.61
Research

I am particularly interested in imaging radiolabelled peptides and proteins for use in diagnosis and therapy of cancer.  These might be radiolabelled with positron emitters such as 68Ga or 64Cu in order to carry out PET imaging, 111In or 99mTc for SPECT imaging or with therapy radioisotopes such as 90Y and 177Lu.

The lab has a long-standing interest in imaging CCK-2 and GRP receptors which are overexpressed in a number of tumour types.

Drug development studies entail using imaging to show specific tissue targeting of small antibodies.  The aim is to use these targeting proteins to carry a therapeutic payload to the site of disease and this work is carried out in collaboration with GSK. We also use radioactive probes such as 18F-FDG and 18F-FLT to monitor response to treatment in vivo.

Major Funding
  • 2018-2021- Barts Charity, Development of a Gallium-68 PET Clinical Imaging Service, £499,993.61
  • 2011-2015- GlaxoSmithKline Research & Development, Evaluation of DAB's in vivo as part of a technology development, £336,608
Recent Publications

New bioconjugated technetium and rhenium folates synthesized by transmetallation reaction with zinc derivatives Borràs J, Foster J, Kashani R et al. Molecules (2021) 26(7)

Bioconjugated technetium carbonyls by transmetalation reaction with zinc derivatives Borràs J, Lecina J, Foster J et al. Bioorganic and Medicinal Chemistry Letters (2021) 37(7)

Simultaneous dual isotope PET-SPECT/CT imaging of pancreatic cancer Dexter K, BROWN N, Foster J et al. (2020) (1)

Cancer associated fibroblast FAK regulates malignant cell metabolism. Demircioglu F, Wang J, Candido J et al. Nature Communications (2020) 11(1) 1290-1290
https://www.ncbi.nlm.nih.gov/pubmed/32157087

Neutron Activated 153Sm Sealed in Carbon Nanocapsules for in Vivo Imaging and Tumor Radiotherapy Wang JTW, Klippstein R, Martincic M et al. ACS Nano (2020) 14(7) 129-141

18F-Trifluoromethanesulfinate Enables Direct C–H 18F-Trifluoromethylation of Native Aromatic Residues in Peptides Kee CW, Tack O, Guibbal F et al. Journal of the American Chemical Society (2020) 142(1) 1180-1185

Organ biodistribution of radiolabelled δγ t cells following liposomal alendronate administration in different mice tumour models Wang JTW, Hodgins NO, Al-Jamal WT et al. Nanotheranostics (2020) 4(7) 71-82

Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer Stella Man YK, Foster J, Carapuça E et al. Scientific Reports (2019) 9(7)

Functionalised LRP1 targeted carbon nanotubes across the blood-brain barrier in vitro and in vivo after intravenous injection Wang J, Kafa H, Rubio N et al. Neuro-Oncology (2019) 21(10) iv3-iv3

AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting Crnogorac-Jurcevic T, Radon T, Shah S et al. Oncotarget (2019) (1)

For additional publications, please click here
Team

Postdoctoral Researchers
Dr Julie FosterDr Roxana Kashani

Biography

I graduated with a BSc (Hons) in Chemistry from University of Natal, Durban, South Africa and went on carry out an MSc by research into the Photochemistry of Sunscreen Constituents at same university.

I then moved to the UK to the Joint Department of Physics at the Institute of Cancer Research in Sutton, Surrey and completed my PhD looking at Development of PET radiotracers for the in vivo assessment of multidrug resistance. I then moved to the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry to carry out a post doc under Prof Stephen Mather.

With the advent of pre-clinical imaging systems this lab developed into the Cancer Imaging Laboratory.